Home › Funds › MPM BioImpact LLC › CGEM
MPM BioImpact LLC position in CGEM
CULLINAN THERAPEUTICS INC · Health Care
MPM BioImpact LLC reported holding 9,731,341 shares of CGEM (CULLINAN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$177.2M, representing 10.81% of its reported portfolio and ranking #1 among its reported holdings. MPM BioImpact LLC has disclosed CGEM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's CGEM position evolved
MPM BioImpact LLC first disclosed a stake in CGEM in Q3 2023 at 7,648,268 shares (US$69.2M). The position peaked in Q2 2026 at 9,731,341 shares, worth US$177.2M. Across 12 filings, MPM BioImpact LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 9,731,341 shares valued at US$177.2M — an increase of 2,083,073 shares quarter over quarter.. Notable position changes include a 27% increase in Q2 2026 (shares fell 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 7.65M | $69.22M | New |
| Q4 2023 | 7.65M | $77.94M | Hold |
| Q1 2024 | 7.65M | $130.33M | Hold |
| Q2 2024 | 7.65M | $133.39M | Hold |
| Q3 2024 | 7.65M | $128.03M | Hold |
| Q4 2024 | 7.65M | $93.16M | Hold |
| Q1 2025 | 7.65M | $57.90M | Hold |
| Q2 2025 | 7.65M | $57.59M | Hold |
| Q3 2025 | 7.65M | $45.35M | Hold |
| Q4 2025 | 7.65M | $79.16M | Hold |
| Q1 2026 | 7.65M | $108.68M | Hold |
| Q2 2026 | 9.73M | $177.21M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CGEM and 13F data
CGEM (CULLINAN THERAPEUTICS INC) is a Health Care company. 37 other funds we track also report a position in CGEM — the largest reported positions include Lynx1 Capital Management LP (US$163.2M), BVF INC/IL (US$104.7M), Kynam Capital Management, LP (US$56.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CGEM
- Lynx1 Capital Management LP 8.96M sh · $163.23M · Q2 2026
- BVF INC/IL 5.75M sh · $104.72M · Q2 2026
- Kynam Capital Management, LP 3.11M sh · $56.71M · Q2 2026
- RTW INVESTMENTS, LP 2.36M sh · $43.05M · Q2 2026
- Siren, L.L.C. 1.89M sh · $34.48M · Q2 2026
- Blue Owl Capital Holdings LP 1.54M sh · $28.04M · Q2 2026
- Venrock Adviser, LLC 1.38M sh · $25.13M · Q2 2026
- BOOTHBAY FUND MANAGEMENT, LLC 1.08M sh · $19.71M · Q2 2026
- Affinity Asset Advisors, LLC 875.76K sh · $15.95M · Q2 2026
- BOONE CAPITAL MANAGEMENT LLC 704.44K sh · $12.83M · Q2 2026
- Elmind Capital, LP 690.00K sh · $12.56M · Q2 2026
- TWIN FOCUS CAPITAL PARTNERS, LLC 595.49K sh · $10.84M · Q2 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held CGEM?
MPM BioImpact LLC has disclosed CGEM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is MPM BioImpact LLC's current position in CGEM?
As of Q2 2026, MPM BioImpact LLC holds 9.73M shares of CGEM (CULLINAN THERAPEUTICS INC), valued at $177.21M, representing 10.81% of its reported portfolio and ranking #1.
Has MPM BioImpact LLC been buying or selling CGEM?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC increased its position in CGEM. The position peaked in Q2 2026 at 9.73M shares.
Which other funds hold CGEM?
Other major institutional holders of CGEM include Lynx1 Capital Management LP, BVF INC/IL, Kynam Capital Management, LP, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.